Gaetano Piccinocchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gaetano Piccinocchi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Piccinocchi
University “Campus Biomedico” of Rome
2 shared publications - Antonio De Vincentis
Department of Internal Medicine and Geriatrics, Campus Bio-Medico University of Rome, 00128 Rome, Italy
1 shared publication - Antonio Picardi
Clinical Medicine and Hepatology Unit, Campus Bio-Medico University, Rome, Italy
1 shared publication Chiara Dell’uNto
Internal Medicine and Hepatology Unit, University Campus Bio-Medico of Rome, Italy
1 shared publication- Davide Arcaniolo
Urology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
1 shared publication - Emiliano Schena
Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Rome, Italy
1 shared publication
Latest Publications
- 10 December 2014
- Published by Springer Nature in World Journal of Urology
- Vol. 33 (5) , 685-689
Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?
We aimed to describe, in a daily clinical practice setting, the demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS), to compare the characteristics of patients receiving 5-alpha-reductase inhibitors (5-ARIs) with those not receiving them and to investigate predictors of 5-ARI prescription. We performed a retrospective observational study using data retrieved from a general practitioners database. Male patients with diagnosis of BPH-LUTS were included. The following demographic and clinical data were available and extracted: age, comorbidities, BPH-LUTS medical therapy, drugs for comorbidities. A subgroup analysis was performed according to the use of 5-ARIs. Factors associated with 5-ARI prescription were assessed with uni- and multivariate analyses. A total of 7,103 patients were identified. Most patients (71.7 %) were aged ≥65 years. Hypertension was present in 64.9 % of patients; it was the most prevalent comorbidity followed by diabetes mellitus, hypercholesterolemia, coronary artery disease and other dyslipidemias. Overall, 38.22 % of patients were treated with 5-ARIs. Mean age of patients taking 5-ARIs was significantly higher. The prevalence of hypertension and the use of antihypertensive drugs were significantly higher among patients receiving 5-ARIs. Older age was an independent predictor of 5-ARI prescription. In a daily clinical practice setting, patients with BPH-LUTS receiving 5-ARIs are significantly older and have significantly higher prevalence of hypertension if compared with patients with BPH-LUTS not receiving 5-ARIs. Older age is an independent predictor of 5-ARI prescription.
- 10 December 2014
- Published by Springer Nature in World Journal of Urology
- Vol. 33 (5) , 685-689
Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?
We aimed to describe, in a daily clinical practice setting, the demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS), to compare the characteristics of patients receiving 5-alpha-reductase inhibitors (5-ARIs) with those not receiving them and to investigate predictors of 5-ARI prescription. We performed a retrospective observational study using data retrieved from a general practitioners database. Male patients with diagnosis of BPH-LUTS were included. The following demographic and clinical data were available and extracted: age, comorbidities, BPH-LUTS medical therapy, drugs for comorbidities. A subgroup analysis was performed according to the use of 5-ARIs. Factors associated with 5-ARI prescription were assessed with uni- and multivariate analyses. A total of 7,103 patients were identified. Most patients (71.7 %) were aged ≥65 years. Hypertension was present in 64.9 % of patients; it was the most prevalent comorbidity followed by diabetes mellitus, hypercholesterolemia, coronary artery disease and other dyslipidemias. Overall, 38.22 % of patients were treated with 5-ARIs. Mean age of patients taking 5-ARIs was significantly higher. The prevalence of hypertension and the use of antihypertensive drugs were significantly higher among patients receiving 5-ARIs. Older age was an independent predictor of 5-ARI prescription. In a daily clinical practice setting, patients with BPH-LUTS receiving 5-ARIs are significantly older and have significantly higher prevalence of hypertension if compared with patients with BPH-LUTS not receiving 5-ARIs. Older age is an independent predictor of 5-ARI prescription.
- 1 October 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (10) , 909-915
Determinants of alanine aminotransferase levels in a large population from Southern Italy: Relationship between alanine aminotransferase and age
- 1 October 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (10) , 909-915
Determinants of alanine aminotransferase levels in a large population from Southern Italy: Relationship between alanine aminotransferase and age